Form 4: Ultragenyx Director Matthew K. Fust Reports Stock and Option Awards

Director Matthew K. Fust reported the acquisition of restricted stock units and stock options in Ultragenyx Pharmaceutical Inc.

Summary

• Matthew K. Fust, a director of Ultragenyx Pharmaceutical Inc., reported changes in beneficial ownership on June 18, 2024.
• Fust was awarded 5,345 restricted stock units (RSUs) under the company's 2023 Incentive Plan, vesting fully on the earlier of the next Annual Meeting of Stockholders or June 18, 2025.
• Fust also acquired options to purchase 9,900 shares of common stock at an exercise price of $37.42, which also vest fully on the earlier of the next Annual Meeting of Stockholders or June 18, 2025.
• Following these transactions, Fust directly owns 20,205 shares of common stock and options for 9,900 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock and option awards, which is neither particularly positive nor negative.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule tied to the Annual Meeting of Stockholders or a specific date encourages continued service and commitment.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the awarded securities.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are common compensation practices in the pharmaceutical industry to incentivize executives and align their interests with shareholders.
• Vesting schedules are typically structured to encourage long-term commitment, often over a period of several years.
• The specific terms of the grants, such as the exercise price and vesting schedule, are generally benchmarked against peer companies to ensure competitiveness.

Stakeholder Impact

• The stock and option awards could have a minor dilutive effect on existing shareholders.
• The awards incentivize the director to work towards increasing shareholder value.

Key Dates